Metraipolis › archive › dc_72c311d22add

Efficacy and safety of cisplatin + docetaxel + 5-FU + leucovorin + methotrexate and epirubicin combination chemotherapy for advanced esophageal cancer — Europe PMC PMID:40570003

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40570003
DOI
10.1371/journal.pone.0326056
License (as archived)
solo-consultazione
Archived
2026-10-08T10:50:56.247Z
SHA-256 of the archived text
1b7947521f2013e36e9240d686eb91bd53319ec61215dab93939f88ae18b45b9
Stable URL of this page
https://metraipolis.com/documento/dc_72c311d22add

How to cite

Efficacy and safety of cisplatin + docetaxel + 5-FU + leucovorin + methotrexate and epirubicin combination chemotherapy for advanced esophageal cancer — Europe PMC PMID:40570003 — Europe PMC (en), https://europepmc.org/article/MED/40570003 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_72c311d22add (Metraipolis archive dc_72c311d22add, sha256 1b7947521f2013e36e9240d686eb91bd53319ec61215dab93939f88ae18b45b9)
BibTeX
@misc{dc72c311d22add,
  title = {Efficacy and safety of cisplatin + docetaxel + 5-FU + leucovorin + methotrexate and epirubicin combination chemotherapy for advanced esophageal cancer — Europe PMC PMID:40570003},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40570003},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_72c311d22add; sha256 1b7947521f2013e36e9240d686eb91bd53319ec61215dab93939f88ae18b45b9},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40570003. Agents can read the archived copy with the MCP tool read_document.